Teacher Retirement System of Texas Sells 9,892 Shares of iRadimed Corporation $IRMD

Teacher Retirement System of Texas lessened its position in shares of iRadimed Corporation (NASDAQ:IRMD) by 24.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,315 shares of the medical equipment provider’s stock after selling 9,892 shares during the period. Teacher Retirement System of Texas’ holdings in iRadimed were worth $2,157,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Calamos Advisors LLC lifted its stake in iRadimed by 98.0% in the 2nd quarter. Calamos Advisors LLC now owns 8,867 shares of the medical equipment provider’s stock valued at $530,000 after acquiring an additional 4,389 shares in the last quarter. Ranger Investment Management L.P. raised its holdings in shares of iRadimed by 7.4% in the second quarter. Ranger Investment Management L.P. now owns 214,840 shares of the medical equipment provider’s stock valued at $12,845,000 after purchasing an additional 14,730 shares during the last quarter. Johnson Investment Counsel Inc. bought a new stake in shares of iRadimed in the second quarter worth $1,534,000. Geode Capital Management LLC boosted its holdings in iRadimed by 6.5% during the second quarter. Geode Capital Management LLC now owns 261,386 shares of the medical equipment provider’s stock worth $15,630,000 after purchasing an additional 15,996 shares during the last quarter. Finally, Spire Wealth Management acquired a new position in iRadimed during the second quarter worth $60,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

Insiders Place Their Bets

In related news, CFO John Glenn sold 15,000 shares of iRadimed stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the completion of the sale, the chief financial officer owned 7,362 shares of the company’s stock, valued at approximately $716,248.98. The trade was a 67.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Roger E. Susi sold 5,000 shares of the company’s stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $100.65, for a total transaction of $503,250.00. Following the completion of the transaction, the chief executive officer owned 2,262,500 shares in the company, valued at approximately $227,720,625. This trade represents a 0.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 60,000 shares of company stock valued at $5,701,100. Company insiders own 36.80% of the company’s stock.

iRadimed Stock Performance

iRadimed stock opened at $97.88 on Friday. The stock has a 50-day simple moving average of $97.35 and a 200 day simple moving average of $81.09. The stock has a market capitalization of $1.25 billion, a P/E ratio of 59.32 and a beta of 1.09. iRadimed Corporation has a 52 week low of $47.48 and a 52 week high of $104.93.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.04. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.The firm had revenue of $21.20 million for the quarter, compared to analyst estimates of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. Research analysts forecast that iRadimed Corporation will post 1.66 earnings per share for the current year.

iRadimed Announces Dividend

The firm also recently declared a special dividend, which was paid on Tuesday, December 30th. Shareholders of record on Wednesday, December 17th were issued a dividend of $0.50 per share. The ex-dividend date of this dividend was Wednesday, December 17th. iRadimed’s dividend payout ratio (DPR) is currently 41.21%.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Lake Street Capital reissued a “buy” rating and set a $100.00 price target on shares of iRadimed in a research report on Monday, November 3rd. Wall Street Zen downgraded iRadimed from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 26th. Roth Mkm set a $90.00 price target on iRadimed in a research report on Friday, October 31st. Zacks Research upgraded iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $95.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.